ORIC Pharmaceuticals to Launch Phase 3 Trial of Prostate Cancer Drug Candidate, Shares Falter
MT Newswires Live
Apr 01
ORIC Pharmaceuticals (ORIC) said Tuesday it has selected its drug candidate rinzimetostat for a Phase 3 trial in advanced prostate cancer.
The experimental drug will be evaluated in combination with the prostate cancer drug darolutamide for the treatment of patients with metastatic castration-resistant prostate cancer who were previously treated with abiraterone.
The trial, expected to enroll around 600 patients from over 250 sites, is set to begin in the first half of 2026.
Shares fell more than 30% in recent after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.